64 filings
8-K
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
8-K
IBRX
ImmunityBio Inc
23 Feb 24
Departure of Directors or Certain Officers
9:28pm
8-K
IBRX
ImmunityBio Inc
2 Jan 24
ImmunityBio Announces $320 Million Investment by Oberland
6:08am
8-K
IBRX
ImmunityBio Inc
11 Sep 23
ImmunityBio Announces $470 Million Equity and Debt Financing
6:25am
8-K
IBRX
ImmunityBio Inc
1 Sep 23
Other Events
8:30am
8-K
nftq mwudf5826nc2
15 Aug 23
Other Events
4:15pm
8-K
n0uvs907bi2ggmczhtj
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
ak98iqt45zh2gpt
20 Jul 23
Other Events
4:07pm
8-K
eg4d5dmc4 xxuou
14 Jun 23
Entry into a Material Definitive Agreement
5:15pm
8-K
jrd wkyvy6
11 May 23
Other Events
6:45am
8-K
xhr7yqn
31 Mar 23
Entry into a Material Definitive Agreement
4:29pm
8-K
5llwkrp3
20 Mar 23
Other Events
8:31am
8-K
txrstrrkj0u1sq29
15 Feb 23
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
9:20am
8-K
a26yjjtzk5b kuq
14 Feb 23
Results of Operations and Financial Condition
5:25pm
8-K
10moma0ne 5f
13 Feb 23
Other Events
8:02am
8-K
88fv muucb2mc
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
8-K
278ir
5 Dec 22
Other Events
10:51am
8-K
yegoba
15 Nov 22
Regulation FD Disclosure
8:42am
8-K
wcwyxn1hoog
2 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
9feioxpq
14 Jun 22
Submission of Matters to a Vote of Security Holders
4:59pm